CN105579439B - 辐射减轻性药物制剂 - Google Patents
辐射减轻性药物制剂 Download PDFInfo
- Publication number
- CN105579439B CN105579439B CN201480038705.0A CN201480038705A CN105579439B CN 105579439 B CN105579439 B CN 105579439B CN 201480038705 A CN201480038705 A CN 201480038705A CN 105579439 B CN105579439 B CN 105579439B
- Authority
- CN
- China
- Prior art keywords
- compound
- day
- alkyl
- compounds
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *CN(CC1OC1*)** Chemical compound *CN(CC1OC1*)** 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820447P | 2013-05-07 | 2013-05-07 | |
| US61/820447 | 2013-05-07 | ||
| PCT/US2014/037110 WO2014182789A2 (en) | 2013-05-07 | 2014-05-07 | Radiomitigating pharmaceutical formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105579439A CN105579439A (zh) | 2016-05-11 |
| CN105579439B true CN105579439B (zh) | 2018-10-19 |
Family
ID=51867859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480038705.0A Active CN105579439B (zh) | 2013-05-07 | 2014-05-07 | 辐射减轻性药物制剂 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9783515B2 (https=) |
| EP (1) | EP2994457B1 (https=) |
| JP (1) | JP2016523830A (https=) |
| KR (1) | KR20160005356A (https=) |
| CN (1) | CN105579439B (https=) |
| AU (1) | AU2014262764B2 (https=) |
| CA (1) | CA2911902A1 (https=) |
| ES (1) | ES2860949T3 (https=) |
| IL (1) | IL242493B (https=) |
| SG (1) | SG11201509194SA (https=) |
| WO (1) | WO2014182789A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| AU2014262764B2 (en) * | 2013-05-07 | 2018-11-15 | The Regents Of The University Of California | Radiomitigating pharmaceutical formulations |
| WO2017156222A1 (en) * | 2016-03-09 | 2017-09-14 | The Regents Of The University Of California | Radiomitigating compounds, compositions and methods related thereto |
| WO2018071887A1 (en) | 2016-10-16 | 2018-04-19 | BCN Biosciences L.L.C. | Methods of treatment and pharmaceutical compositions using bcn057 or bcn512 |
| US20190046524A1 (en) * | 2017-08-08 | 2019-02-14 | BCN Biosciences L.L.C. | Methods of treating radiation induced gastrointestinal syndrome (rigs) and related disease states using compound 512 |
| WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| NZ503788A (en) | 1997-10-27 | 2002-11-26 | Agouron Pharma | 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases |
| US6407120B1 (en) * | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| IT1313594B1 (it) * | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Bisplatino complessi attivi per via orale. |
| JP4365102B2 (ja) | 2001-04-26 | 2009-11-18 | コーロン ライフ サイエンス インク | 新規なスルホンアミド誘導体、その中間体化合物、及びその製造方法、並びにスルホンアミド誘導体を含む薬剤学的組成物 |
| WO2005046599A2 (en) * | 2003-11-14 | 2005-05-26 | Temple University - Of The Commonwealth System Of Higher Education | Alpha, beta-unsaturated sulfoxides for treating proliferative disorders |
| JP2005232101A (ja) * | 2004-02-20 | 2005-09-02 | Rikogaku Shinkokai | セレコキシブアミノアルキル誘導体 |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| MY140912A (en) * | 2004-07-26 | 2010-01-29 | Du Pont | Mixtures of anthranilamide invertebrate pest control agents |
| US7615570B2 (en) | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| WO2007029078A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Succinimide and glutarimide derivatives as adrenergic receptor antagonists |
| EA200802415A1 (ru) | 2006-06-09 | 2009-06-30 | Икос Корпорейшн | Замещенные фенилуксусные кислоты в качестве dp-2-антагонистов |
| US20080207621A1 (en) | 2006-09-28 | 2008-08-28 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| WO2010003023A2 (en) | 2008-07-01 | 2010-01-07 | Zacharon Pharmaceuticals, Inc. | Heparan sulfate inhibitors |
| GB0815781D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| WO2010111713A2 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | N-linked glycan biosynthesis modulators |
| US8546397B2 (en) * | 2010-12-20 | 2013-10-01 | The Ohio State University Research Foundation | DNA methylation inhibitors |
| US9217000B2 (en) * | 2011-02-18 | 2015-12-22 | Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education | Targeted nitroxide agents |
| AU2014262764B2 (en) * | 2013-05-07 | 2018-11-15 | The Regents Of The University Of California | Radiomitigating pharmaceutical formulations |
-
2014
- 2014-05-07 AU AU2014262764A patent/AU2014262764B2/en active Active
- 2014-05-07 WO PCT/US2014/037110 patent/WO2014182789A2/en not_active Ceased
- 2014-05-07 EP EP14794084.5A patent/EP2994457B1/en active Active
- 2014-05-07 KR KR1020157034769A patent/KR20160005356A/ko not_active Ceased
- 2014-05-07 US US14/889,719 patent/US9783515B2/en active Active
- 2014-05-07 CA CA2911902A patent/CA2911902A1/en not_active Abandoned
- 2014-05-07 JP JP2016513039A patent/JP2016523830A/ja active Pending
- 2014-05-07 SG SG11201509194SA patent/SG11201509194SA/en unknown
- 2014-05-07 CN CN201480038705.0A patent/CN105579439B/zh active Active
- 2014-05-07 ES ES14794084T patent/ES2860949T3/es active Active
-
2015
- 2015-11-08 IL IL242493A patent/IL242493B/en active IP Right Grant
-
2016
- 2016-04-08 US US15/094,192 patent/US9840483B2/en active Active
-
2017
- 2017-11-14 US US15/812,321 patent/US20180162827A1/en not_active Abandoned
Non-Patent Citations (4)
| Title |
|---|
| "Antiplasmodial activity of piperazine sulfonamides";Derek C. Martyn等;《Bioorganic & Medicinal Chemistry Letters》;20091031;第20卷;第218-221页 * |
| "Chemoselective N-Benzenesulfonylation of Aliphatic Amines";Ho-Kyun Kim等;《Bull.Korean Chem.Soc.》;20031231;第24卷(第11期);第1655-1658页 * |
| "Synthesis of 6-sulfamoyl-4-oxoquinoline-3-carboxylic acid derivatives as integrase antagonists with anti-HIV activity";Zai Gang Luo等;《Chinese Chemical Letters》;20091231;第20卷;第789-792页 * |
| Zai Gang Luo等."Synthesis of 6-sulfamoyl-4-oxoquinoline-3-carboxylic acid derivatives as integrase antagonists with anti-HIV activity".《Chinese Chemical Letters》.2009,第20卷第789-792页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2860949T3 (es) | 2021-10-05 |
| WO2014182789A3 (en) | 2014-12-11 |
| AU2014262764B2 (en) | 2018-11-15 |
| US20160221976A1 (en) | 2016-08-04 |
| AU2014262764A1 (en) | 2015-12-17 |
| SG11201509194SA (en) | 2015-12-30 |
| US20180162827A1 (en) | 2018-06-14 |
| CA2911902A1 (en) | 2014-11-13 |
| CN105579439A (zh) | 2016-05-11 |
| WO2014182789A2 (en) | 2014-11-13 |
| IL242493B (en) | 2020-08-31 |
| EP2994457B1 (en) | 2021-01-06 |
| IL242493A0 (en) | 2016-02-01 |
| JP2016523830A (ja) | 2016-08-12 |
| US9840483B2 (en) | 2017-12-12 |
| EP2994457A2 (en) | 2016-03-16 |
| KR20160005356A (ko) | 2016-01-14 |
| US9783515B2 (en) | 2017-10-10 |
| US20160090369A1 (en) | 2016-03-31 |
| EP2994457A4 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2820827T3 (es) | Formas sólidas de un compuesto modulador de quinasas | |
| US12370195B2 (en) | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | |
| CN105579439B (zh) | 辐射减轻性药物制剂 | |
| KR101923250B1 (ko) | 유방암의 치료 | |
| CN102497862B (zh) | 使用ck2调节剂的组合治疗 | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| ES2757598T3 (es) | Compuestos para el tratamiento de las enfermedades relacionadas con la vía mTOR | |
| KR20140041457A (ko) | 신경 장애 치료용 신규 조성물 | |
| AU2021236532A1 (en) | Methods and compositions for treating aging-associated impairments using CCR3-inhibitors | |
| KR20160067103A (ko) | 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물 | |
| WO2016040527A1 (en) | Metabolism probes for therapy and diagnosis | |
| JP2022527401A (ja) | 炎症性障害を治療するための化合物および方法 | |
| US10266490B2 (en) | Radioprotector compounds | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| AU2017342551B2 (en) | Methods of treatment and pharmaceutical compositions using BCN057 or BCN512 | |
| JP2020040978A (ja) | サルコイドーシスを処置するための１，３−プロパンジスルホン酸またはその薬学的に許容される塩の使用 | |
| US12042493B2 (en) | Pharmaceutical compounds for use in treating Huntington's disease | |
| US20210308138A1 (en) | Tissue transglutaminase modulators for medicinal use | |
| WO2020191002A1 (en) | Compositions and methods for treating cushing's disease | |
| BR112021004938A2 (pt) | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 | |
| WO2017156222A1 (en) | Radiomitigating compounds, compositions and methods related thereto | |
| JP2024533229A (ja) | Ｂｃｎ０５７、ｂｃｎ０７７および類似体を用いた治療の方法 | |
| WO2017052359A1 (en) | Anti-angiogenic agents and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |